Anika Therapeutics Net Profit Margin 2006-2021 | ANIK

Anika Therapeutics net profit margin from 2006 to 2021. Net profit margin can be defined as net Income as a portion of total sales revenue.
Anika Therapeutics Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2021-09-30 $0.15B $-0.01B -3.45%
2021-06-30 $0.14B $-0.01B -8.76%
2021-03-31 $0.13B $-0.03B -20.77%
2020-12-31 $0.13B $-0.02B -18.32%
2020-09-30 $0.13B $-0.00B -3.13%
2020-06-30 $0.13B $0.01B 8.73%
2020-03-31 $0.13B $0.03B 22.40%
2019-12-31 $0.12B $0.03B 23.48%
2019-09-30 $0.11B $0.03B 27.68%
2019-06-30 $0.11B $0.03B 27.52%
2019-03-31 $0.11B $0.03B 28.18%
2018-12-31 $0.11B $0.02B 17.92%
2018-09-30 $0.11B $0.02B 17.59%
2018-06-30 $0.11B $0.02B 16.67%
2018-03-31 $0.11B $0.02B 17.27%
2017-12-31 $0.11B $0.03B 27.68%
2017-09-30 $0.11B $0.03B 27.68%
2017-06-30 $0.11B $0.03B 29.73%
2017-03-31 $0.11B $0.03B 29.52%
2016-12-31 $0.10B $0.03B 31.73%
2016-09-30 $0.11B $0.04B 33.96%
2016-06-30 $0.10B $0.04B 33.65%
2016-03-31 $0.10B $0.03B 34.00%
2015-12-31 $0.09B $0.03B 32.98%
2015-09-30 $0.09B $0.03B 32.56%
2015-06-30 $0.08B $0.03B 30.95%
2015-03-31 $0.09B $0.03B 31.03%
2014-12-31 $0.11B $0.04B 36.19%
2014-09-30 $0.10B $0.04B 35.92%
2014-06-30 $0.10B $0.04B 36.36%
2014-03-31 $0.09B $0.03B 35.11%
2013-12-31 $0.08B $0.02B 28.00%
2013-09-30 $0.08B $0.02B 23.38%
2013-06-30 $0.07B $0.02B 20.27%
2013-03-31 $0.07B $0.01B 17.81%
2012-12-31 $0.07B $0.01B 16.67%
2012-09-30 $0.07B $0.01B 16.42%
2012-06-30 $0.07B $0.01B 17.14%
2012-03-31 $0.07B $0.01B 15.15%
2011-12-31 $0.06B $0.01B 12.50%
2011-09-30 $0.06B $0.01B 9.84%
2011-06-30 $0.06B $0.00B 7.02%
2011-03-31 $0.06B $0.00B 5.45%
2010-12-31 $0.06B $0.00B 7.27%
2010-09-30 $0.05B $0.00B 7.84%
2010-06-30 $0.05B $0.01B 10.42%
2010-03-31 $0.04B $0.01B 11.36%
2009-12-31 $0.04B $0.01B 12.20%
2009-09-30 $0.04B $0.01B 12.82%
2009-06-30 $0.04B $0.00B 10.81%
2009-03-31 $0.04B $0.00B 11.11%
2008-12-31 $0.04B $0.00B 11.11%
2008-09-30 $0.04B $0.01B 13.51%
2008-06-30 $0.04B $0.01B 16.67%
2008-03-31 $0.03B $0.01B 17.65%
2007-12-31 $0.03B $0.01B 19.35%
2007-09-30 $0.03B $0.01B 18.52%
2007-06-30 $0.03B $0.00B 16.00%
2007-03-31 $0.03B $0.00B 15.38%
2006-12-31 $0.03B $0.00B 14.81%
2006-09-30 $0.03B $0.00B 15.38%
2006-06-30 $0.03B $0.01B 20.00%
2006-03-31 $0.03B $0.01B 20.69%
2005-12-31 $0.03B $0.01B 20.69%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.572B $0.130B
Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.477B 7.93
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.874B 21.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.457B 0.00
Arcus Biosciences (RCUS) United States $3.257B 0.00
Emergent Biosolutions (EBS) United States $2.378B 8.55
Myovant Sciences (MYOV) United Kingdom $1.780B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.529B 0.00
Zymeworks (ZYME) Canada $0.908B 0.00
Ambrx Biopharma (AMAM) United States $0.407B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09